| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
Review |
Clinical Endocrinology Branch, NIDDK, National Institutes of Health, Bethesda MD 20892–1758, USA
Correspondence: Dr LeRoith MD, PhD.Clinical Endocrinology Branch, NIDDK, Room 8D12, Building 10, National Institutes of Health, Bethesda, MD 20892–1758 Derek{at}helix.nih.gov
In MCF-7 breast cancer cells, the insulin-like growth factor 1 receptor (IGF-1R) and the oestrogen receptor (ER) are coexpressed and the two signalling systems are engaged in a crosstalk that results in synergistic growth. However, coupling between the signalling cascades is poorly understood. Oestradiol enhances IGF-1R signalling by inducing the expression of insulin receptor substrate 1 (IRS-1), a substrate of the IGF-1R. Oestradiol induced expression of IRS-1 results in enhanced tyrosine phosphorylation of IRS-1 after IGF-1 stimulation, followed by enhanced mitogen activated protein kinase, phosphoinositide 3' kinase, and Akt activation. Oestradiol can also potentiate the effect of IGF-1 on the expression of cyclin D1 and cyclin E, and on the phosphorylation of the retinoblastoma protein (RB). These effects are greatly diminished in SX13 cells, which exhibit a 50% reduction in IGF-1R expression but few functional IGF-1Rs at the surface. Oestradiol and IGF-1 regulate the expression of two cyclin dependent kinase inhibitors, p21 and p27, differently. Whereas IGF-1 increases p21 expression and reduces p27 expression, oestradiol has no effect on p21. In summary, in MCF-7 cells, oestrogen potentiates the effect of IGF-1 on IGF-1R signalling and its effects on certain cell cycle components.
Key Words: breast cancer • oestrogen receptor • insulin-like growth factor 1 receptor • cell cycle
This article has been cited by other articles:
|
|
 |
|
  T. Kogai, E. Ohashi, M. S. Jacobs, S. Sajid-Crockett, M. L. Fisher, Y. Kanamoto, and G. A. Brent Retinoic Acid Stimulation of the Sodium/Iodide Symporter in MCF-7 Breast Cancer Cells Is Meditated by the Insulin Growth Factor-I/Phosphatidylinositol 3-Kinase and p38 Mitogen-Activated Protein Kinase Signaling Pathways J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1884 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-J. A. Tsai, K. M. McCormick, D. A. Brazeau, and G. A. Brazeau Estrogen Effects on Skeletal Muscle Insulin-Like Growth Factor 1 and Myostatin in Ovariectomized Rats Experimental Biology and Medicine, November 1, 2007; 232(10): 1314 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ravikumar, G. Perez-Liz, L. Del Vale, D. R. Soprano, and K. J. Soprano Insulin Receptor Substrate-1 Is an Important Mediator of Ovarian Cancer Cell Growth Suppression by All-trans Retinoic Acid Cancer Res., October 1, 2007; 67(19): 9266 - 9275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Lee, C. Y. Han, J. W. Yang, C. Smith, S. K. Kim, E. Y.-H. P. Lee, S. G. Kim, and K. W. Kang Induction of Glutathione Transferase in Insulin-Like Growth Factor Type I Receptor-Overexpressed Hepatoma Cells Mol. Pharmacol., October 1, 2007; 72(4): 1082 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. vanTol, S. Missan, J. Crack, S. Moser, W. H. Baldridge, P. Linsdell, and E. A. Cowley Contribution of KCNQ1 to the regulatory volume decrease in the human mammary epithelial cell line MCF-7 Am J Physiol Cell Physiol, September 1, 2007; 293(3): C1010 - C1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Andreu-Vieyra, R. Chen, and M. M. Matzuk Effects of Granulosa Cell-Specific Deletion of Rb in Inha-{alpha} Null Female Mice Endocrinology, August 1, 2007; 148(8): 3837 - 3849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dhar, S. Banerjee, G. Dhar, K. Sengupta, and S. K. Banerjee Insulin-like Growth Factor-1 (IGF-1) Induces WISP-2/CCN5 via Multiple Molecular Cross-talks and Is Essential for Mitogenic Switch by IGF-1 Axis in Estrogen Receptor-Positive Breast Tumor Cells Cancer Res., February 15, 2007; 67(4): 1520 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Lorincz and S Sukumar Molecular links between obesity and breast cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 279 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cui, H.-J. Kim, I. Kuiatse, H. Kim, P. H. Brown, and A. V. Lee Epidermal Growth Factor Induces Insulin Receptor Substrate-2 in Breast Cancer Cells via c-Jun NH2-Terminal Kinase/Activator Protein-1 Signaling to Regulate Cell Migration. Cancer Res., May 15, 2006; 66(10): 5304 - 5313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Osipo, K. Meeke, H. Liu, D. Cheng, S. Lim, A. Weichel, and V. C. Jordan Trastuzumab Therapy for Tamoxifen-Stimulated Endometrial Cancer Cancer Res., September 15, 2005; 65(18): 8504 - 8513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Greco, M G Elia, A Muscella, S Romano, C Storelli, and S Marsigliante Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture J. Endocrinol., August 1, 2005; 186(2): 291 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Koda, M Sulkowska, L Kanczuga-Koda, and S Sulkowski Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases J. Clin. Pathol., June 1, 2005; 58(6): 645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mendez, I. Azcoitia, and L. M. Garcia-Segura Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analysing neuroprotective mechanisms J. Endocrinol., April 1, 2005; 185(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chaturvedi and D. K. Sarkar Involvement of Protein Kinase C-Dependent Mitogen-Activated Protein Kinase p44/42 Signaling Pathway for Cross-Talk between Estradiol and Transforming Growth Factor-{beta}3 in Increasing Basic Fibroblast Growth Factor in Folliculostellate Cells Endocrinology, February 1, 2004; 145(2): 706 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Boyd Insulin and Cancer Integr Cancer Ther, December 1, 2003; 2(4): 315 - 329. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Eng-Wong, S. D. Hursting, D. Venzon, S. N. Perkins, and J. A. Zujewski Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1468 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Salas, S. A. Reddy, J. L. Clifford, R. J. Davis, A. Kikuchi, S. M. Lippman, and D. G. Menter Alleviating the Suppression of Glycogen Synthase Kinase-3{beta} by Akt Leads to the Phosphorylation of cAMP-response Element-binding Protein and Its Transactivation in Intact Cell Nuclei J. Biol. Chem., October 17, 2003; 278(42): 41338 - 41346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Decensi, U. Veronesi, R. Miceli, H. Johansson, L. Mariani, T. Camerini, M. G. Di Mauro, E. Cavadini, G. De Palo, A. Costa, et al. Relationships between Plasma Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-3 and Second Breast Cancer Risk in a Prevention Trial of Fenretinide Clin. Cancer Res., October 15, 2003; 9(13): 4722 - 4729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yu, X.-O. Shu, B. D. L. Li, Q. Dai, Y.-T. Gao, F. Jin, and W. Zheng Joint Effect of Insulin-like Growth Factors and Sex Steroids on Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1067 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Cui, P. Zhang, W. Deng, S. Oesterreich, Y. Lu, G. B. Mills, and A. V. Lee Insulin-Like Growth Factor-I Inhibits Progesterone Receptor Expression in Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway: Progesterone Receptor as a Potential Indicator of Growth Factor Activity in Breast Cancer Mol. Endocrinol., April 1, 2003; 17(4): 575 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Krajcik, N. D. Borofsky, S. Massardo, and N. Orentreich Insulin-like Growth Factor I (IGF-I), IGF-binding Proteins, and Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1566 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Vasudevan, S. Ogawa, and D. Pfaff Estrogen and Thyroid Hormone Receptor Interactions: Physiological Flexibility by Molecular Specificity Physiol Rev, October 1, 2002; 82(4): 923 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-H. Shen, J.-H. Zhou, S. R. Broussard, G. G. Freund, R. Dantzer, and K. W. Kelley Proinflammatory Cytokines Block Growth of Breast Cancer Cells by Impairing Signals from a Growth Factor Receptor Cancer Res., August 15, 2002; 62(16): 4746 - 4756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Levenson, K. M. Svoboda, K. M. Pease, S. A. Kaiser, B. Chen, L. A. Simons, B. D. Jovanovic, P. A. Dyck, and V. C. Jordan Gene Expression Profiles with Activation of the Estrogen Receptor {alpha}-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor Cancer Res., August 1, 2002; 62(15): 4419 - 4426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Stull, M. M. Richert, A. V. Loladze, and T. L. Wood Requirement for IGF-I in Epidermal Growth Factor-Mediated Cell Cycle Progression of Mammary Epithelial Cells Endocrinology, May 1, 2002; 143(5): 1872 - 1879. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Molecular Pathology | Journal of Clinical Pathology |
